The report 'Success Rates in Biotech - Going The Wrong Way' summarises our review of 211 public biotech companies comprising over 1,500 drug development projects. We have studied the clinical pipelines going back to 2002 based on financial reports and found a striking difference of success probabilities compared to data derived form pharmaceutical companies.
In the report, the success rates resulting from the analysis are discussed, especially in view of their implications to the management of biotech firms and investments in these companies.
